Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleLack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia.
Author(s)Kalliomäki J, Philipp A, Baxendale J, Annas P, Karlsten R, Segerdahl M.
Journal, Volume, IssueClin Exp Pharmacol Physiol. 2012 Apr;39(4):336-42. doi: 10.1111/j.1440-1681.2012.05674.x.
Major outcome(s)The cannabinoid had no significant effect on acute experimental pain.
IndicationPainAbstract
MedicationNabilone

The aim of the present study was to investigate the effects of nabilone on
capsaicin-induced pain and hyperalgesia, as well as on biomarkers of cannabinoid
central nervous system (CNS) effects. A randomized, double-blind,
placebo-controlled, crossover study was conducted in 30 healthy male volunteers
receiving single doses of nabilone (1, 2 or 3 mg). Pain intensity after
intradermal capsaicin injections in the forearm was assessed by continuous visual
analogue scale (0-100 mm). Capsaicin cream was applied to the calf to induce
hyperalgesia. Primary hyperalgesia was assessed by measuring heat pain
thresholds, whereas secondary hyperalgesia was assessed by measuring the area
where light tactile stimulation was felt to be painful. Pain and hyperalgesia
were measured at baseline and 2-3.5 h after dosing. The CNS effects were assessed
at baseline and up to 24 h after dosing using visual analogue mood scales for
feeling 'stimulated', 'anxious', 'sedated' and 'down'. Plasma samples for
pharmacokinetic analysis were obtained up to 24 h after drug administration.
Nabilone did not significantly attenuate either ongoing pain or primary or
secondary hyperalgesia, whereas dose-dependent CNS effects were observed from 1.5
to 6 h after dosing, being maximal at 4-6 h. Plasma concentrations of nabilone
and its metabolite carbinol were maximal 1-2 h after dosing. Adverse events (AE)
were common on nabilone treatment. Four subjects withdrew due to pronounced CNS
AE (anxiety, agitation, altered perception, impaired consciousness). Although
nabilone had marked CNS effects, no analgesic or antihyperalgesic effects were
observed.

Route(s)Oral
Dose(s)1-3 mg
Duration (days)1
Participants30 healthy subjects
DesignControlled study
Type of publicationMedical journal
Address of author(s)AstraZeneca R&D, Södertälje, Sweden. jarkko.kalliomaki@astrazeneca.com
Full text

[Back to Overview]  [IACM Homepage]


up